Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results
Identifieur interne : 000119 ( France/Analysis ); précédent : 000118; suivant : 000120Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results
Auteurs : N. Andrews ; J. Mcmenamin ; H. Durnall ; J. Ellis ; A. Lackenby ; C. Robertson [France] ; B. Wissmann ; S. Cottrell ; B. Smyth ; C. Moore ; R. Gunson ; M. Zambon ; D. Fleming ; R. PebodySource :
English descriptors
- mix :
- DNA Time Factors Treatment Outcome Vaccination/statistics & numerical data, H1N1 Subtype/classification/genetics/immunology/*isolation & purification Influenza A Virus, H3N2 Subtype/classification/genetics/immunology/*isolation & purification Influenza B virus/genetics/*immunology/isolation & purification Influenza Vaccines/*administration & dosage/immunology/therapeutic use Influenza, Human/*epidemiology/immunology/*prevention & control/virology Male Middle Aged Primary Health Care Reverse Transcriptase Polymerase Chain Reaction Seasons *Sentinel Surveillance Sequence Analysis, Adolescent Adult Aged Case-Control Studies Child Female Great Britain/epidemiology Hemagglutination Inhibition Tests Humans Influenza A Virus.
Abstract
The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000074
- to stream Hal, to step Curation: 000074
- to stream Hal, to step Checkpoint: 000148
- to stream Main, to step Merge: 000778
- to stream Main, to step Curation: 000777
- to stream Main, to step Exploration: 000777
- to stream France, to step Extraction: 000119
Links to Exploration step
Hal:hal-01262537Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results</title><author><name sortKey="Andrews, N" sort="Andrews, N" uniqKey="Andrews N" first="N." last="Andrews">N. Andrews</name></author><author><name sortKey="Mcmenamin, J" sort="Mcmenamin, J" uniqKey="Mcmenamin J" first="J." last="Mcmenamin">J. Mcmenamin</name></author><author><name sortKey="Durnall, H" sort="Durnall, H" uniqKey="Durnall H" first="H." last="Durnall">H. Durnall</name></author><author><name sortKey="Ellis, J" sort="Ellis, J" uniqKey="Ellis J" first="J." last="Ellis">J. Ellis</name></author><author><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A." last="Lackenby">A. Lackenby</name></author><author><name sortKey="Robertson, C" sort="Robertson, C" uniqKey="Robertson C" first="C." last="Robertson">C. Robertson</name><affiliation wicri:level="1"><hal:affiliation type="institution" xml:id="struct-334118" status="INCOMING"> <orgName>Health Protection Scotland</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </hal:affiliation><country>France</country></affiliation></author><author><name sortKey="Wissmann, B" sort="Wissmann, B" uniqKey="Wissmann B" first="B." last="Wissmann">B. Wissmann</name></author><author><name sortKey="Cottrell, S" sort="Cottrell, S" uniqKey="Cottrell S" first="S." last="Cottrell">S. Cottrell</name></author><author><name sortKey="Smyth, B" sort="Smyth, B" uniqKey="Smyth B" first="B." last="Smyth">B. Smyth</name></author><author><name sortKey="Moore, C" sort="Moore, C" uniqKey="Moore C" first="C." last="Moore">C. Moore</name></author><author><name sortKey="Gunson, R" sort="Gunson, R" uniqKey="Gunson R" first="R." last="Gunson">R. Gunson</name></author><author><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name></author><author><name sortKey="Fleming, D" sort="Fleming, D" uniqKey="Fleming D" first="D." last="Fleming">D. Fleming</name></author><author><name sortKey="Pebody, R" sort="Pebody, R" uniqKey="Pebody R" first="R." last="Pebody">R. Pebody</name></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01262537</idno><idno type="halId">hal-01262537</idno><idno type="halUri">https://hal.archives-ouvertes.fr/hal-01262537</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01262537</idno><date when="2014">2014</date><idno type="wicri:Area/Hal/Corpus">000074</idno><idno type="wicri:Area/Hal/Curation">000074</idno><idno type="wicri:Area/Hal/Checkpoint">000148</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000148</idno><idno type="wicri:Area/Main/Merge">000778</idno><idno type="wicri:Area/Main/Curation">000777</idno><idno type="wicri:Area/Main/Exploration">000777</idno><idno type="wicri:Area/France/Extraction">000119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results</title><author><name sortKey="Andrews, N" sort="Andrews, N" uniqKey="Andrews N" first="N." last="Andrews">N. Andrews</name></author><author><name sortKey="Mcmenamin, J" sort="Mcmenamin, J" uniqKey="Mcmenamin J" first="J." last="Mcmenamin">J. Mcmenamin</name></author><author><name sortKey="Durnall, H" sort="Durnall, H" uniqKey="Durnall H" first="H." last="Durnall">H. Durnall</name></author><author><name sortKey="Ellis, J" sort="Ellis, J" uniqKey="Ellis J" first="J." last="Ellis">J. Ellis</name></author><author><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A." last="Lackenby">A. Lackenby</name></author><author><name sortKey="Robertson, C" sort="Robertson, C" uniqKey="Robertson C" first="C." last="Robertson">C. Robertson</name><affiliation wicri:level="1"><hal:affiliation type="institution" xml:id="struct-334118" status="INCOMING"> <orgName>Health Protection Scotland</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </hal:affiliation><country>France</country></affiliation></author><author><name sortKey="Wissmann, B" sort="Wissmann, B" uniqKey="Wissmann B" first="B." last="Wissmann">B. Wissmann</name></author><author><name sortKey="Cottrell, S" sort="Cottrell, S" uniqKey="Cottrell S" first="S." last="Cottrell">S. Cottrell</name></author><author><name sortKey="Smyth, B" sort="Smyth, B" uniqKey="Smyth B" first="B." last="Smyth">B. Smyth</name></author><author><name sortKey="Moore, C" sort="Moore, C" uniqKey="Moore C" first="C." last="Moore">C. Moore</name></author><author><name sortKey="Gunson, R" sort="Gunson, R" uniqKey="Gunson R" first="R." last="Gunson">R. Gunson</name></author><author><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name></author><author><name sortKey="Fleming, D" sort="Fleming, D" uniqKey="Fleming D" first="D." last="Fleming">D. Fleming</name></author><author><name sortKey="Pebody, R" sort="Pebody, R" uniqKey="Pebody R" first="R." last="Pebody">R. Pebody</name></author></analytic></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term> DNA Time Factors Treatment Outcome Vaccination/statistics & numerical data</term><term> H1N1 Subtype/classification/genetics/immunology/*isolation & purification Influenza A Virus</term><term> H3N2 Subtype/classification/genetics/immunology/*isolation & purification Influenza B virus/genetics/*immunology/isolation & purification Influenza Vaccines/*administration & dosage/immunology/therapeutic use Influenza</term><term> Human/*epidemiology/immunology/*prevention & control/virology Male Middle Aged Primary Health Care Reverse Transcriptase Polymerase Chain Reaction Seasons *Sentinel Surveillance Sequence Analysis</term><term>Adolescent Adult Aged Case-Control Studies Child Female Great Britain/epidemiology Hemagglutination Inhibition Tests Humans Influenza A Virus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"> <p>The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.</p> </div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Andrews, N" sort="Andrews, N" uniqKey="Andrews N" first="N." last="Andrews">N. Andrews</name><name sortKey="Cottrell, S" sort="Cottrell, S" uniqKey="Cottrell S" first="S." last="Cottrell">S. Cottrell</name><name sortKey="Durnall, H" sort="Durnall, H" uniqKey="Durnall H" first="H." last="Durnall">H. Durnall</name><name sortKey="Ellis, J" sort="Ellis, J" uniqKey="Ellis J" first="J." last="Ellis">J. Ellis</name><name sortKey="Fleming, D" sort="Fleming, D" uniqKey="Fleming D" first="D." last="Fleming">D. Fleming</name><name sortKey="Gunson, R" sort="Gunson, R" uniqKey="Gunson R" first="R." last="Gunson">R. Gunson</name><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A." last="Lackenby">A. Lackenby</name><name sortKey="Mcmenamin, J" sort="Mcmenamin, J" uniqKey="Mcmenamin J" first="J." last="Mcmenamin">J. Mcmenamin</name><name sortKey="Moore, C" sort="Moore, C" uniqKey="Moore C" first="C." last="Moore">C. Moore</name><name sortKey="Pebody, R" sort="Pebody, R" uniqKey="Pebody R" first="R." last="Pebody">R. Pebody</name><name sortKey="Smyth, B" sort="Smyth, B" uniqKey="Smyth B" first="B." last="Smyth">B. Smyth</name><name sortKey="Wissmann, B" sort="Wissmann, B" uniqKey="Wissmann B" first="B." last="Wissmann">B. Wissmann</name><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name></noCountry><country name="France"><noRegion><name sortKey="Robertson, C" sort="Robertson, C" uniqKey="Robertson C" first="C." last="Robertson">C. Robertson</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= France
|étape= Analysis
|type= RBID
|clé= Hal:hal-01262537
|texte= Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results
}}
| This area was generated with Dilib version V0.6.33. |  |